WINTON GROUP Ltd Purchases 32,222 Shares of QuidelOrtho Co. (NASDAQ:QDEL)

WINTON GROUP Ltd grew its holdings in shares of QuidelOrtho Co. (NASDAQ:QDEL - Free Report) by 23.4% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 169,961 shares of the company's stock after acquiring an additional 32,222 shares during the quarter. WINTON GROUP Ltd owned about 0.25% of QuidelOrtho worth $7,572,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also bought and sold shares of the stock. Blue Trust Inc. lifted its stake in QuidelOrtho by 188.0% during the fourth quarter. Blue Trust Inc. now owns 1,293 shares of the company's stock worth $58,000 after purchasing an additional 844 shares during the last quarter. Spire Wealth Management purchased a new position in shares of QuidelOrtho during the 4th quarter valued at about $74,000. KBC Group NV lifted its position in QuidelOrtho by 122.9% in the 4th quarter. KBC Group NV now owns 3,437 shares of the company's stock worth $153,000 after buying an additional 1,895 shares during the last quarter. LPL Financial LLC purchased a new stake in QuidelOrtho in the fourth quarter worth approximately $221,000. Finally, Captrust Financial Advisors bought a new position in QuidelOrtho during the third quarter valued at approximately $238,000. 99.00% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently issued reports on QDEL shares. StockNews.com cut shares of QuidelOrtho from a "buy" rating to a "hold" rating in a research note on Saturday, February 15th. Royal Bank of Canada cut their price target on shares of QuidelOrtho from $64.00 to $61.00 and set an "outperform" rating for the company in a research report on Thursday, February 13th. UBS Group lifted their price objective on QuidelOrtho from $43.00 to $45.00 and gave the stock a "neutral" rating in a report on Thursday, February 13th. Jefferies Financial Group initiated coverage on QuidelOrtho in a research note on Tuesday, December 10th. They issued a "hold" rating and a $43.00 target price for the company. Finally, Citigroup upgraded QuidelOrtho from a "neutral" rating to a "buy" rating and raised their price target for the stock from $44.00 to $50.00 in a research report on Wednesday, December 11th. Four equities research analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. Based on data from MarketBeat.com, QuidelOrtho currently has an average rating of "Hold" and an average target price of $51.20.

QuidelOrtho Stock Performance

Shares of QDEL stock traded down $0.09 on Monday, reaching $34.80. The stock had a trading volume of 113,043 shares, compared to its average volume of 951,360. The company has a 50 day simple moving average of $40.14 and a 200 day simple moving average of $41.40. The stock has a market cap of $2.35 billion, a P/E ratio of -1.15 and a beta of 0.10. QuidelOrtho Co. has a 1 year low of $29.74 and a 1 year high of $49.45. The company has a debt-to-equity ratio of 0.71, a quick ratio of 0.69 and a current ratio of 1.22.

QuidelOrtho (NASDAQ:QDEL - Get Free Report) last released its quarterly earnings results on Wednesday, February 12th. The company reported $0.63 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.07 by ($0.44). QuidelOrtho had a negative net margin of 72.84% and a positive return on equity of 3.78%. Equities research analysts expect that QuidelOrtho Co. will post 2.3 EPS for the current year.

QuidelOrtho Profile

QuidelOrtho Corporation provides diagnostic testing solutions. The company operates through Labs, Transfusion Medicine, Point-of-Care, and Molecular Diagnostics business units. The Labs business unit provides clinical chemistry laboratory instruments and tests that measure target chemicals in bodily fluids for the evaluation of health and the clinical management of patients; immunoassay laboratory instruments and tests, which measure proteins as they act as antigens in the spread of disease, antibodies in the immune response spurred by disease, or markers of proper organ function and health; testing products to detect and monitor disease progression across a spectrum of therapeutic areas; and specialized diagnostic solutions.